

ATTACHMENT A-2: SUPPORTING DOCUMENTS FOR MOTHERS

A.2.1 Consent Form

A.2.2 Informed Consent Form-Focus Groups

Attachment A-2.1

Consent Form

SAMPLE CONSENT FORM

I, _____, authorize
(NAME OF CONSUMER)

(NAME OR GENERAL DESIGNATION OF PROGRAM MAKING DISCLOSURE)

to disclose to:

1. _____
2. _____
3. _____
(NAME OF PERSONS OR ORGANIZATIONS TO WHICH DISCLOSURE IS TO BE MADE)

the following information:

(NATURE OF THE INFORMATION, AS LIMITED AS POSSIBLE)

The purpose of the disclosure authorized herein is to:

(PURPOSE OF DISCLOSURE, AS SPECIFIC AS POSSIBLE)

I understand that my records are protected under the Federal regulations governing Confidentiality of Alcohol and Drug Abuse Patient Records, 42 CFR Part 2, and cannot be disclosed without my written consent unless otherwise provided for in the regulations. I also understand that I may revoke this consent at any time except to the extent that action has been taken in reliance on it, and that in any event this consent expires automatically as follows:

(SPECIFICATION OF THE DATE, EVENT, OR CONDITION UPON WHICH THIS CONSENT EXPIRES)

(Date) (Print Name) (Signature of Consumer)

(Date) (Print Name) (Signature of Parent, Guardian or Authorized Representative when required)

The following notice must accompany a disclosure of information concerning a consumer in alcohol/drug abuse treatment, made to grantee organization with the consent of such consumer. This notice is not to be altered in anyway.

PROHIBITION ON REDISCLOSURE OF INFORMATION CONCERNING CONSUMER IN ALCOHOL OR DRUG ABUSE TREATMENT STATEMENT

This information has been disclosed to you from records protected by Federal confidentiality rules (42 CFR Part 2). The Federal rules prohibit you from making any further disclosure of this information unless further disclosure is expressly permitted by the written consent of the person to whom it pertains or as otherwise permitted by 42 CFR Part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. The Federal rules restrict any use of the information to criminally investigate or prosecute any alcohol or drug abuse patient.

Informed Consent for Data Collection

The purpose of your participation in this data collection activity is to collect information to assess the effectiveness of treatment services received by you (and/or your children) here at

_____. You and/or your child's participation is encouraged but

(Name of Treatment Agency)

completely voluntary. The expected duration of this data collection activity is approximately fourteen months. You and/or your child have the right to stop participating in this data collection activity at any time without discontinuing your treatment services for yourself or your child.

The risk in participating in this data collection is seen as minimal. However, because some questions are of a sensitive nature, you or your child may feel uncomfortable. To minimize this risk, precautions have been taken to select questions that are frequently asked in Substance Abuse treatment programs. In the event you or your child becomes uncomfortable answering any of these questions, there will be clinically trained staff to provide any necessary support services.

If you have any questions regarding this data collection activity, please contact

Name/Title/Address/Phone Number

By signing below, I am voluntarily agreeing to have myself and or my child participate in this data collection activity.

Name (Print Name)	Signature of Child	Date
-------------------	--------------------	------

Name (Print Name)	Signature of Parent, Guardian or Authorized Rep. when required	Date
-------------------	--	------

Signature of project staff/witness

Date

This form is valid until _____. (Insert Date)

Attachment A-2.2

Informed Consent Form-Focus Groups

INFORMED CONSENT FORM

Title: Evaluation of Pregnant and Postpartum Women (PPW)

Study Description: Westat, (a private research company), is conducting a cross-site evaluation of PPW programs on behalf of the Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT). The purpose of this study is to evaluate the effectiveness of PPW programs that received Federal funds and obtain information about how they can be improved. As part of this study, Westat is conducting site visits to PPW programs and focus groups with PPW clients. You are being asked to participate in this focus group because of your participation in this PPW program. This focus group will last about one to one and a half hours.

Risks and Benefits: There are no known risks for participating in this focus group. If you feel uncomfortable with any of the questions being asked you do not have to respond and may leave the focus group at any point. There is no direct benefit to you in participating in this focus group; however, your responses along with the responses from others will be used to inform future PPW programs and improve existing PPW programs.

Privacy: All information provided during this focus group will be kept private. However, if threats to your safety (e.g., suicidal thoughts) or the safety of others (e.g., child abuse and/or neglect, homicidal thoughts) are mentioned during the focus group discussion, we will report this information to PPW program staff.

During the focus group, only your first names will be used. Your responses will be combined with information provided by other clients (including clients in other PPW programs funded by CSAT) and reported in aggregate form. To ensure your privacy, we will not link an individual's name with a specific response when reporting our results. The audiotape recording of this focus group will be kept in locked file cabinets and no names will be used when creating the transcript of this focus group.

Right to Withdraw: You may refuse to participate in this focus group and you may stop participating at any time. You also do not have to answer any questions that you do not want to answer.

Voluntary Consent: Your signature below indicates that you have read the information provided above and have decided to participate. Your signature also indicates that you have given permission to be audiotape recorded during the focus group. You can keep a copy of this form.

Any questions that you may have about this study may be answered by Wendy Kissin, Ph.D. (Project Director) 301-294-3885; and any questions about your rights as a research participant may be answered by the IRB Administrator of the IRB Office, Westat (301-610-8828).

Participant's Signature

Date